- Catalent’s net revenue for the 3rd quarter was $1.07 billion, marking a 3.6% increase year on year. However, this fell short of the estimated $1.12 billion.
- Biologics net revenue stood at $461 million, showcasing a decrease of 2.9% compared to the same period last year. This was also lower than the projected $509.1 million.
- The Adjusted Ebitda for the company came in at $163 million, reflecting a significant 55% growth from last year. Despite this growth, it was below the forecasted $191.7 million.
- Biologics EBITDA was reported at $49 million, presenting a noticeable jump from $6 million last year. Again, this figure was under the estimated $77.5 million.
- Pharmaceuticals & Consumer Health net revenue climbed 8.9% to $613.0 million, slightly surpassing the estimated $607.9 million.
- EBITDA for Pharmaceuticals & Consumer Health saw a 22% year-on-year increase to reach $153.0 million, exceeding the predicted $147.9 million.
- The 3Q Loss Per Share was 56 Cents.
- Catalent foresees the deal with Novo Holdings wrapping up towards the end of the year.
- With regard to ratings, there are 2 buys, 10 holds, and 0 sells.
Catalent Inc on Smartkarma
Analyst coverage of Catalent Inc on Smartkarma has been initiated by Baptista Research with a bullish outlook. In their report titled “Catalent: Initiation of Coverage – How Their Ongoing Strategic Review Could Unleash Unprecedented Growth! – Major Drivers,” Baptista Research highlights the healthcare tech solutions provider, Catalent Inc. The report discusses Catalent’s solid start to the fiscal year 2024, despite market turbulence. Management’s focus on improving cash flow through better working capital management and increased analytical rigor around capital expenditure spending is noted as positive.
A look at Catalent Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Smartkarma’s Smart Scores offer insights into the long-term outlook for Catalent Inc. Despite varying scores across different factors, Catalent Inc stands out with a strong momentum score of 5. This indicates a positive trend in the company’s stock performance and market sentiment, suggesting a promising future ahead.
While Catalent Inc scores moderately on value, growth, and resilience, with scores of 3, 2, and 2 respectively, its low dividend score of 1 may deter income-focused investors. Overall, Catalent Inc‘s strong momentum score coupled with its diverse delivery technologies and development solutions position the company well for long-term growth and success in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
